

# The Antimicrobial Activities of Extract and Compounds Isolated from *Brillantaisia lamium*

Jean De Dieu Tamokou<sup>1</sup>, Jules Roger Kuate<sup>1</sup>, Mathieu Tene<sup>2</sup>, Timothée Julbe-  
lin Kenla Nwemeguella<sup>2</sup>,  
Pierre Tane<sup>2</sup>

## Abstract

**Background:** *Brillantaisia lamium* is an erect branched herb, which grows to a height of 1.50 m in moist tropical areas, both in full sun and partial shade. In Cameroon, the aerial part of this plant is used in the treatment of various microbial infections such as skin diseases and infections of urinary tract. The aim of this study was to evaluate the antimicrobial activities of CH<sub>2</sub>Cl<sub>2</sub>: MeOH (1:1) extract, fractions and compounds from the aerial part of *B. lamium*.

**Methods:** The plant was dried and extracted by maceration in CH<sub>2</sub>Cl<sub>2</sub>: MeOH (1:1 v/v). Structures of the compounds from the CH<sub>2</sub>Cl<sub>2</sub>: MeOH (1:1) soluble fraction were determined by spectroscopic methods and compared with published data. The broth micro dilution method was used to evaluate the antimicrobial activities against bacteria and fungal species.

**Results:** Four known compounds: aurantiamide acetate (1), lupeol (2), lespedin (3), sitosterol 3-O-β-D-glucopyranoside (4) and a mixture of sterols: campesterol (5), stigmasterol (6) and β-sitosterol (7) were isolated from CH<sub>2</sub>Cl<sub>2</sub>: MeOH (1:1) extract of *B. lamium* aerial parts. The crude extract, fractions and isolated compounds exhibited both antibacterial and antifungal activities that varied with microorganism (MIC=6.25 – 1000 µg/ml). Compound 3 was the most active (MIC=6.25 – 100 µg/ml) while *Staphylococcus aureus*, *Enterococcus faecalis*, *Candida tropicalis* and *Cryptococcus neoformans* were the most sensitive to all the tested compounds.

**Conclusion:** The overall results of this study indicate that the CH<sub>2</sub>Cl<sub>2</sub>: MeOH (1:1) extract and some of isolated compounds have interesting antimicrobial properties and can be used for the treatment of fungal and bacterial infections.

**Iran J Med Sci 2011; 36(1): 24-31.**

**Keywords** • Antifungal • antibacterial • phytochemicals

<sup>1</sup>Departments of Biochemistry,  
<sup>2</sup>Chemistry, Faculty of Sciences,  
University of Dschang,  
Cameroon.

## Correspondence:

Jean De Dieu Tamokou PhD,  
Department of Biochemistry,  
Faculty of Sciences,  
University of Dschang,  
P.O. Box 67, Dschang,  
Cameroon  
**Tel:** +237 77 000897  
**Fax:** +237 33 451102  
**Email:** [jtamokou@yahoo.fr](mailto:jtamokou@yahoo.fr)  
Received: 26 May 2010  
Revised: 10 October 2010  
Accepted: 31 October 2010

## Introduction

The emergence of human pathogenic microorganisms that are resistant to major classes of antibiotics has increased in recent years, due to the indiscriminate use of antimicrobial drugs.<sup>1</sup> This has caused many clinical problems in the treatment of infectious diseases, and the antibiotics commonly used are sometimes associated with adverse effects such as hypersensitivity, allergic reaction and immunosuppression in the host.<sup>2</sup> Thus, the search for the discovery of new antimicrobial agents

is an urgent need. Cameroonian traditional medicine is increasingly solicited through tradipractitioners and herbalists in the treatments of infectious diseases. On the other hand, about 80% of citizens in developing countries use traditional medicine based on plant products.<sup>3</sup> Traditionally, dry herbs are used either boiled in water like tea or as an infusion to treat systemic bacterial and fungal infections, or are directly applied on the skin or nails in a plaster form to treat local infections.<sup>4</sup>

Some species of the Acanthaceae family present antimicrobial activities.<sup>5</sup> Previous chemical studies with species of this family were related to the isolation of alkaloids, iridoids, lignans, flavonoids, terpenoids and phenylpropanoids glycosides.<sup>6</sup> *Brillantaisia lamium* (Nees) Benth is an erect branched herb from Acanthaceae family, which has a height of about 1.5 m and is found in moist tropical areas growing both in full sun and partial shade.<sup>7</sup> The aerial part of this plant is used in Cameroon in the treatment of various microbial infections such as skin diseases and infections of urinary tract. However, no phytochemical and biological studies have been reported on *B. lamium*. As a continuation of our chemical and biological studies of Cameroonian medicinal plants,<sup>8-13</sup> we have investigated the CH<sub>2</sub>Cl<sub>2</sub>: MeOH (1:1) extract of the aerial part of *B. lamium*, and have reported herein the isolation of a mixture of three sterols and four pure compounds together with their antibacterial and antifungal activities.

## Materials and Methods

### Plant Material

The aerial parts of *B. lamium* Benth, were collected in January 2008 in Korup, South-west region of Cameroon (figure 1). The botanical



Figure 1: Aerial parts of *Brillantaisia lamium*.

identification of the plant was done at the National Herbarium, Yaounde, Cameroon, (voucher specimen No. 34376/HNC). The plant material was air-dried at room temperature and ground into fine powder.

### Microorganisms

The test microorganisms included three bacteria and two fungi. They were mostly reference strains obtained from the American Type Culture Collection (ATCC, Rockville, USA): *Staphylococcus aureus* ATCC25922, *Enterococcus faecalis* ATCC10541, *Salmonella typhi* ATCC6539, *Candida albicans* ATCC9002 and *Candida tropicalis* ATCC750. Also included, were one clinical isolate of *Proteus mirabilis* and one strain of *Cryptococcus neoformans* IP95026 collected from Pasteur Institute of Yaoundé (Cameroon) and Paris (France) respectively. They were maintained at +4°C on Agar slants in the Laboratory of Microbiology and Antimicrobial Substances (LAMAS) of the Faculty of Sciences, University of Dschang, Cameroon, where the antimicrobial tests were performed. The strains were subcultured on fresh appropriate agar plate 24 hours prior to any antimicrobial test.

### Extraction, Fractionation and Isolation of Compounds

Previously dried and powdered aerial parts of *B. lamium* (2.50 kg) were macerated with CH<sub>2</sub>Cl<sub>2</sub>: MeOH (1:1 v/v) (3 × 15 L, 72 hours) at room temperature (25±1°C) to obtain a crude extract (184 g) after evaporation of solvent under reduced pressure at 40°C. One hundred and seventy nine grams (179 g) of this extract were successively extracted with *n*-hexane (1.5 L), followed by CH<sub>2</sub>Cl<sub>2</sub> (1.50 L). Thin layer chromatography (TLC) analysis showed that the *n*-hexane and CH<sub>2</sub>Cl<sub>2</sub> extracts were qualitatively the same. They were thus combined and a portion of 47 g was subjected to silica gel column chromatography (Ø 80 mm × L 600 mm) and eluted with *n*-hexane-EtOAc (10:0, 9:1, 8:2, 7:3, 1:1 and 0:10 each 6 L) and EtOAc-MeOH (10:0, 19:1, 9:1 and 0:10 each 6 L). Fifty five fractions of 300 ml each were collected and combined on the basis of TLC profile to give five major fractions A - E (A: 1-12; B: 13-25; C: 26-38; D: 39-45; E: 46-55). Fraction A (10.20 g) contained mostly fatty material and was not further investigated. Fraction B (11.80 g) was purified on a silica gel column (Ø 60 mm × L 400 mm) with *n*-hexane-EtOAc (10:0, 90:10 and 9:1 each 2 L) to afford lupeol (2) (20 mg; R<sub>f</sub>=0.60, *n*-hexane-EtOAc, 9:1) and a mixture of campesterol (5), stigmasterol (6)

and  $\beta$ -sitosterol (7) (22 mg; Rf=0.53, *n*-hexane-EtOAc, 9:1) in an estimated proportion of 1:4:1.50 (GC-MS). Fraction C (5.60 g) was subjected to silica gel column chromatography ( $\varnothing$  50 mm  $\times$  L 600 mm) eluted with *n*-hexane-EtOAc (10:0, 9:1, 4:1, 3:2, 2:3 and 0:10, each 1.50 L) to yield aurantiamide acetate (1) (30 mg; Rf=0.46, *n*-hexane-EtOAc, 7:3). Fraction D crystallized in methanol to give sitosterol 3-O- $\beta$ -D-glucopyranoside (4) (160 mg; Rf=0.70, CH<sub>2</sub>Cl<sub>2</sub>-MeOH, 9:1). Fraction E (10.20 g) was submitted to silica gel column chromatography and eluted with CH<sub>2</sub>Cl<sub>2</sub>:MeOH (19:1, 17:3, 4:1, 7:3, each 2.50 L) followed by purification through Sephadex LH-20 gel column chromatography using CH<sub>2</sub>Cl<sub>2</sub>:MeOH (1:1) to yield lespedin (3) (21 mg, Rf=0.35, CH<sub>2</sub>Cl<sub>2</sub>-MeOH, 9:1).

#### Identification of isolated compounds

The structural identification of compounds 1-4 was established using spectroscopic analysis, especially, NMR spectra in conjunction with 2D experiments and direct comparison with published information,<sup>6,11,14,15</sup> and authentic specimens obtained in our laboratory for some cases. Melting points of isolated compounds were uncorrected and determined on a Büchi SMP-20 melting point apparatus and with a Reichert microscope. Infra-red spectra were measured on a Shimadzu FTIR-8400S spectrophotometer and the UV spectra were recorded with a Shimadzu UV-3101 PC, spectrophotometer. Electron impact-mass spectrometry (ionization voltage 70 eV) and High resolution-electron impact-mass spectrometry spectra were measured with a Finnigan MAT double focusing spectrometer Model 8230.<sup>1</sup> <sup>1</sup>H-NMR (500 MHz) and,<sup>5</sup> <sup>13</sup>C-NMR (125 MHz) spectra were recorded in CDCl<sub>3</sub> using a Bruker-Avance-500 MHz NMR spectrometer and Trimethylsilyl as internal standard. The mixture of sterols was only identified by gas chromatography-mass spectrometry. Gas chromatography-mass spectrometry (GC-MS) data were obtained with an Agilent 6890N Network GC system/5975 Inert X L Mass Selective Detector at 70 eV and 20°C. The GC column was a CP-Sil 8 CB LB, fused silica capillary column (0.25 mm  $\times$  30 m, film thickness 0.25  $\mu$ m). The initial temperature was 50°C for 1 min, and then heated at 10°C/min to 300°C. For the carrier gas, helium was used with a flow rate of 1.20 ml/min. Kovat's retention index (KI) was determined using a calibration curve of n-alkanes.

#### Antimicrobial Assays

##### Determination of Diameters of Inhibition Zones

The diameters of inhibition zones were determined by disc diffusion method as described

by Tamokou and co-workers,<sup>10</sup> with some modifications. Stock solutions of test samples were prepared in 10% v/v aqueous dimethylsulfoxide (DMSO) solution (Fisher chemicals) at concentrations of 100 mg/ml (for crude extract and fractions) and 10 mg/ml (for pure compounds). The inocula of microorganisms were prepared from 24 h old broth cultures. The absorbance was read at 600 nm and adjusted with sterile physiological solution to match that of a 0.5 McFarland standard solution. From the prepared microbial solutions, other dilutions with sterile physiological solution were prepared to give a final concentration of 10<sup>6</sup> colony-forming units (CFU) per milliliter for bacteria and 2x10<sup>5</sup> spores per milliliter for yeasts. Bottles containing 19.80 ml of sterile molten Sabouraud Dextrose Agar (Conda, Madrid, Spain) or Mueller Hinton Agar (MHA) (Conda, Madrid, Spain) were maintained in a water bath at 45°C to prevent solidification of the medium, and were aseptically inoculated with 200  $\mu$ l of bacteria or yeast suspension. Microbial inoculum and medium were well mixed and dispensed into sterile 90 mm diameter Petri dishes and allowed to solidify at room temperature in a sterile cupboard. After solidification, discs of 6 mm in diameter previously impregnated with 10  $\mu$ l of test samples were placed aseptically on the solid plates. This gave a charge of 1 mg or 100  $\mu$ g of test substances per disc. The Petri dishes were left at +4°C for 2 h to allow extracts and compounds to diffuse from the discs into the medium. The test media were then incubated at 35°C for 24 h (for bacteria) and 48 h (for yeasts). Antimicrobial activity was evaluated by measuring the clear zone of growth inhibition on agar surface around the discs. The assay was done in triplicates. Gentamicin (Sigma-Aldrich, Steinheim, Germany) and nystatin (Merck, Darmstadt, Germany) were used as positive controls for bacteria and yeasts respectively at 10  $\mu$ g per disc. Dimethylsulfoxide solution (10% v/v) was used as a negative control.

##### Determination of minimum inhibitory concentrations (MICs) and minimum microbicidal concentrations (MMCs)

Minimum inhibitory concentration values were determined by broth micro dilution method as reported by Nyaa and co-workers.<sup>16</sup> The test samples were first of all dissolved in DMSO. The solution obtained was then added to Mueller Hinton Broth (MHB) for bacteria or Sabouraud Dextrose Broth (SDB) for yeasts to give a final concentration of 2000  $\mu$ g/ml.

This was serially diluted two folds to obtain a concentration range of 0.48 to 2000 µg/ml. One hundred microliters of each concentration was added into each well (96-wells microplate) containing 95 µl of MHB or SDB and 5 µl of inoculum ( $10^6$  CFU/ml for bacteria and  $5 \times 10^5$  spores/ml for yeasts) to obtain final concentrations varying from 0.12 to 1000 µg/ml. The final concentration of DMSO in the well was less than 1% (v/v). Preliminary analysis with 1% (v/v) DMSO did not inhibit the growth of the test organisms. The negative control wells consisted of 195 µl of MHB or SDB and 5 µl of the inoculum. The plates were covered with sterile lids, then agitated to mix the contents of wells using a plate shaker and incubated at 35°C for 24 hours for bacteria, 48 hours for *Candida sp*, or 72 hours for *Cryptococcus neoformans*. The assays were repeated thrice. The MICs of samples were detected following the addition of 50 µl of a 0.20 mg/ml *p*-iodonitrotetrazolium violet (INT) solution followed by incubation at 35°C for 30 min. The colorless tetrazolium salt acts as an electron acceptor and is reduced to a red-colored formazan product by biologically active microorganisms. Where microbial growth was inhibited, the solution in the well remained clear after incubation with INT. Minimum inhibitory concentrations were defined as the lowest sample concentrations that prevented this color change indicating a complete inhibition of microbial growth.

For the determination of MMCs, a portion of

liquid (5 µl) from each well that showed no growth of microorganism was plated on MHA or SDA and incubated at 35°C for 24 hours for bacteria, 48 hours for *Candida sp*, or 72 hours for *Cryptococcus neoformans*. The lowest concentration that yielded no revival of growth after this subculturing was taken as the MMCs.<sup>16</sup> Gentamicin and nystatin were used as positive controls for bacteria and yeasts respectively.

#### Statistical Analysis

Statistical analysis was performed using Statistical Package for Social Sciences (SPSS) for Window software version 12.0. The inhibition diameters of test substances were expressed as mean±standard deviation. Group comparisons were done using one way analysis of variance (ANOVA) followed by Waller-Duncan Post Hoc test. A value of  $P < 0.05$  was considered statistically significant.

### Results


Four known compounds: aurantiamide acetate (1), lupeol (2), lespedin (3), sitosterol 3-O-β-D-glucopyranoside (4) and a mixture of sterols: campesterol (5), stigmasterol (6) and β-sitosterol (7) were isolated from CH<sub>2</sub>Cl<sub>2</sub>: MeOH (1:1) extract of *B. lamium* aerial parts (figure 2).

The results of the antimicrobial activity showed that the CH<sub>2</sub>Cl<sub>2</sub>: MeOH (1:1) extract, fractions B-E and all the isolated compounds showed both antifungal and antibacterial activities that varied among the microbial strains

**Table 1:** Diameters (mean±SD) of inhibition zones of the CH<sub>2</sub>Cl<sub>2</sub>: MeOH (1:1) extract and fractions and compounds isolated from *Brillantaisia lamium*

Test sub-stances	Diameters of inhibition zones (in mm)						
	Bacteria				Fungi		
	<i>Enterococcus faecalis</i>	<i>Staphylococcus aureus</i>	<i>Salmonella typhi</i>	<i>Proteus mirabilis</i>	<i>Candida albicans</i>	<i>Candida tropicalis</i>	<i>Cryptococcus neoformans</i>
Crude extract	20.00±0.50 <sup>d</sup>	18.00±1.0 <sup>a</sup>	21.00±0.50 <sup>a</sup>	20.00±0.00 <sup>a</sup>	15.00±0.00 <sup>d</sup>	17.50±1.00 <sup>a</sup>	15.50±1.00 <sup>a</sup>
Fraction A	na	na	na	na	na	na	na
Fraction B	14.50±1.0 <sup>a</sup>	16.00±0.00 <sup>b</sup>	na	na	na	15.00±0.00 <sup>b</sup>	na
Fraction C	17.50±0.50 <sup>c</sup>	15.00±0.50 <sup>c</sup>	na	na	13.50±1.00 <sup>a</sup>	14.50±0.50 <sup>b</sup>	12.50±1.00 <sup>d</sup>
Fraction D	21.00±0.50 <sup>b</sup>	22.50±0.50 <sup>d</sup>	23.50±0.50 <sup>d</sup>	24.00±0.00 <sup>e</sup>	17.50±0.50 <sup>c</sup>	20.00±1.0 <sup>c</sup>	18.00±0.00 <sup>b</sup>
Fraction E	na	12.50±0.50 <sup>e</sup>	na	na	11.00±0.50 <sup>d</sup>	14.50±0.50 <sup>b</sup>	na
Mixture of sterols	14.50±0.50 <sup>a</sup>	13.00±0.00 <sup>e</sup>	na	12.50±0.50 <sup>b</sup>	na	11.00±0.00 <sup>d</sup>	na
1	11.00±0.00 <sup>d</sup>	16.00±0.00 <sup>b</sup>	13.00±0.50 <sup>b</sup>	15.00±0.00 <sup>c</sup>	15.50±0.50 <sup>b</sup>	13.00±0.00 <sup>e</sup>	17.00±0.50 <sup>c</sup>
2	10.00±0.00 <sup>e</sup>	12.50±1.00 <sup>e</sup>	na	12.00±0.00 <sup>b</sup>	11.50±0.50 <sup>d</sup>	na	12.50±1.00 <sup>d</sup>
3	20.50±0.50 <sup>b</sup>	26.50±0.50 <sup>f</sup>	26.00±0.00 <sup>c</sup>	23.50±1.00 <sup>e</sup>	15.50±0.50 <sup>b</sup>	15.00±0.00 <sup>b</sup>	18.00±0.50 <sup>b</sup>
4	11.50±0.00 <sup>d</sup>	13.50±0.50 <sup>e</sup>	na	14.50±0.50 <sup>c</sup>	13.00±0.00 <sup>a</sup>	15.00±0.50 <sup>b</sup>	15.00±1.00 <sup>a</sup>
Gentamicin	20.50±1.50 <sup>b</sup>	25.50±1.00 <sup>f</sup>	24.00±0.50 <sup>d</sup>	19.00±0.00 <sup>d</sup>	nt	nt	nt
Nystatin	nt	nt	nt	nt	25.50±0.50 <sup>e</sup>	22.00±1.00 <sup>c</sup>	26.00±0.50 <sup>f</sup>

Zone diameters were determined at 1 mg (for the crude extract and fractions), 100 µg (for the isolated compounds and mixture of sterol) or 10 µg (for gentamicin and nystatin) per spot; 1 mg, 100 µg and 10 µg were the minimum charges of a disc. For the same column, mean diameters of inhibition zones of the test samples bearing different superscript letters (a, b, c, d, e, f) are significantly different ( $p < 0.05$ ) compared to other mean values, and those carrying the same superscripts are not significantly different. The results are the mean values of triplicate tests measured in two directions after 24-48 h incubation at 35 °C.; na: not active; nt: not tested; aurantiamide acetate (1); lupeol (2); lespedin (3); sitosterol 3-O-β-D-glucopyranoside (4); a mixture of sterols: campesterol (5); stigmasterol (6); β-sitosterol (7).



**Figure 2:** Chemical structures of aurantiamide acetate (1), lupeol (2), lespedin (3), sitosterol 3-O-β-D-glucopyranoside (4), a mixture of sterols: campesterol (5), stigmasterol (6) and β-sitosterol (7) isolated from *B. lamium*.

(tables 1-3). Gram-positive bacteria were more sensitive to the test samples as compared with Gram-negative bacteria (table 1). Fraction A was found to be not active, and *Salmonella typhi* and *Candida albicans* were respectively the most resistant strains for bacteria and yeasts against all the tried samples. Fractionation enhanced the antimicrobial activity of the crude extract in fraction D (MIC=62.50-125 µg/ml). However, these activities decreased in other fractions. The results of MIC and MMC values were in agreement with the above observations (tables 2-3). The antimicrobial activity of compound 1 (MIC=50-200 µg/ml) was

almost found to be comparable to that of gentamicin (MIC=12.50-100 µg/ml), but lower than that of nystatin (MIC=1.56-6.25 µg/ml) (table 2). Compound 3 (MIC=6.25-25 µg/ml) was the most active substance among the test samples (MIC=12.50-400 µg/ml). Moreover, its antibacterial activity was higher than that of gentamicin (MIC=12.50-100 µg/ml), which was used as a reference drug.

## Discussion

The findings of the present study showed that there were differences between the antimicrobial

**Table 2:** Minimum inhibitory concentrations (MIC) of the CH<sub>2</sub>Cl<sub>2</sub>: MeOH (1:1) extract, fractions and compounds of *Brillantaisia lamium*

Test substances	Minimum inhibitory concentrations (in µg/ml)						
	Bacteria				Fungi		
	<i>Enterococcus faecalis</i>	<i>Staphylococcus aureus</i>	<i>Salmonella typhi</i>	<i>Proteus mirabilis</i>	<i>Candida albicans</i>	<i>Candida tropicalis</i>	<i>Cryptococcus neoformans</i>
Crude extract	125	250	125	62.50	500	250	250
Fraction A	na	na	na	na	na	na	na
Fraction B	1000	500	na	na	na	500	na
Fraction C	250	500	na	na	1000	500	1000
Fraction D	125	125	62.50	62.50	125	62.50	125
Fraction E	na	500	na	na	1000	500	na
Mixture of sterols	50	100	na	200	na	400	na
1	100	50	50	100	50	100	12.50
2	400	200	na	200	200	na	200
3	25	6.25	12.50	12.50	50	50	6.25
4	100	100	na	100	200	100	50
Gentamicin	12.50	50	50	100	nt	nt	nt
Nystatin	nt	nt	nt	nt	1.56	6.25	1.56

Tabulated values are the means of three trials which did not show any variation (SD=0); na: not active at concentrations up to 400 µg/ml (for pure compounds and mixture of sterols) or 1 mg/ml (for crude extract and fractions); nt: not tested; gentamicin and nystatin are used as reference antibiotics for bacteria and yeasts respectively; aurantiamide acetate (1); lupeol (2); lespeidin (3); sitosterol 3-O-β-D-glucopyranoside (4); a mixture of sterols: campesterol (5); stigmasterol (6); β-sitosterol (7).

**Table 3:** Minimum microbicidal concentrations (MMC) of the CH<sub>2</sub>Cl<sub>2</sub>: MeOH (1:1) extract, fractions and compounds of *Brillantaisia lamium*

Test substances	Minimum microbicidal concentrations (in µg/ml)						
	Bacteria				Fungi		
	<i>Enterococcus faecalis</i>	<i>Staphylococcus aureus</i>	<i>Salmonella typhi</i>	<i>Proteus mirabilis</i>	<i>Candida albicans</i>	<i>Candida tropicalis</i>	<i>Cryptococcus neoformans</i>
Crude extract	250	250	250	125	500	500	250
Fraction A	na	na	na	na	na	na	na
Fraction B	1000	500	na	na	na	1000	na
Fraction C	500	500	na	na	1000	1000	1000
Fraction D	125	250	125	62.50	250	125	125
Fraction E	na	500	na	na	1000	500	na
Mixture of sterols	100	100	na	200	na	400	na
1	100	50	50	100	50	100	25
2	400	200	na	200	200	na	200
3	25	12.50	12.50	25	100	50	12.50
4	200	100	na	100	200	200	100
Gentamicin	12.50	50	50	100	nt	nt	nt
Nystatin	nt	nt	nt	nt	1.56	6.25	1.56

Tabulated values are the means of three trials which did not show any variation (SD=0); na: not active at concentrations up to 400 µg/ml (for pure compounds and mixture of sterols) or 1 mg/ml (for crude extract and fractions); nt: not tested; gentamicin and nystatin are used as reference antibiotics for bacteria and yeasts respectively; aurantiamide acetate (1); lupeol (2); lespeidin (3); sitosterol 3-O-β-D-glucopyranoside (4); a mixture of sterols: campesterol (5); stigmasterol (6); β-sitosterol (7).

activities of crude extract and those of fractions. This suggests that the aerial part of *B. lamium* contains several antifungal and antibacterial principles with different polarities as shown by the phytochemical study. The fractionation of the crude extract enhanced its antimicrobial activity in fraction D, and reduced those of other fractions. This indicates that the active principles might be more concentrated in fraction D and more diluted in other fractions. All the isolated compounds showed antimicrobial activities on at least one microorganism. Such a finding supports the traditional use of this plant in the treatment of infectious diseases. The antimicrobial properties of some individual flavonoids, sterols and triterpenes of plant origin were documented.<sup>9,16-19</sup> Compounds 1 and 2 displayed

antibacterial as well as antifungal activities. Comparable results were obtained by Ragasa et al.<sup>19</sup> and Singh and Singh.<sup>20</sup>

The known antimicrobial mechanisms associated to each group of chemicals to which the isolated compounds belong may explain the antimicrobial potency of the crude extract, fractions and compounds from *B. lamium*. Membrane disruption has been suggested as one of the likely mechanisms of action.<sup>21,22</sup> This might also explain the antimicrobial activities of compounds 2 (triterpene), 4, 5, 6 and 7 (sterols).<sup>21,22</sup> The activity of flavonoids such as compound 3 might be due to their ability to complex with bacteria cell wall,<sup>21</sup> and therefore, inhibiting the microbial growth.

The antimicrobial activities varied with the bacterial and fungal species. These variations may be due to genetic differences between the microorganisms. The results of MMC values (table 3) indicated that a cidal effect of many of the tried samples could be expected. Moreover, a keen look at the results of MIC (table 2) and MMC (table 3), showed that the MIC values obtained were four times lesser than the MMCs on the corresponding (sensitive) microorganisms, confirming the microbicidal effects of the concerned samples.<sup>9,23</sup> This is interesting in view of the perspective of developing new antibacterial drugs from natural products. To the best of our knowledge, this is the first report on the antimicrobial activities of the crude extract, fractions and compounds from *B. lamium*.

The overall results of this study can be considered as very promising in the perspective of new drugs discovery from plant sources, especially when the medical importance of tested microorganisms is considered. *Staphylococcus aureus* is a major cause of community and hospital-associated infection with an estimated mortality of around 7-10%.<sup>24</sup> Moreover, about 2% of patients in Cameroon, are infected by *Staphylococcus* spp.<sup>25</sup> Each year, some 500,000 patients in American hospitals contract a staphylococcal infection.<sup>24</sup> Such findings stress the importance of finding an antibiotic against which the organism (*Staphylococcus aureus*) is sensitive. This pathogen was found to be sensitive to the crude extract, fractions and isolated compounds.

About 77% of immune-deficient patients' death is attributable to microscopic fungi, such as *Candida* species and *Cryptococcus neoformans*.<sup>26</sup> Also, 75% of women, during their lives, would have had at least one episode of vulvo-vaginitis candidiasis, which is considered as the second most common form of vaginitis after bacterial vaginosis.<sup>27</sup> Typhoid fever caused by *Salmonella typhi* continues to be a significant public health problem in developing countries in general and in Sub-Saharan Africa in particular. Generally, at least three of the samples tested (i.e. Fraction D, compounds 1 and 3) in this study prevented the growth of all microbial strains.

## Conclusion

The results of this study indicate that the CH<sub>2</sub>Cl<sub>2</sub>: MeOH (1:1) extract from aerial parts of *B. lamium* might represents a potential source of plant drugs for the treatment of fungal and bacterial diseases. Also, all the isolated compounds found active in this study could be

useful for the development of new antimicrobial drugs. However, pharmacological and toxicological studies, currently going on in our laboratory, will be necessary to confirm this hypothesis.

## Acknowledgment

This research was supported by the International Sciences Program, Uppsala University, Sweden (ISP, Grant No CAM: 02, to Prof Tane), the International Foundation for Science, Stockholm, Sweden, and the Organization for the Prohibition of Chemical Weapons, The Hague, The Netherlands (IFS-OPCW, Grant No F/ 4238-1, to Dr Tene). We thank Pr. Karsten Krohn, Department of Chemistry, University of Paderborn, Germany and Pr. SF Kouam of "Ecole Normale Supérieure de Yaoundé", University of Yaounde 1, Cameroon for the NMR spectra analyses.

**Conflict of Interest:** None declared

## References

- 1 Karaman I, Sahin F, Güllüce M, et al. Antimicrobial activity of aqueous and methanol extracts of *Juniperus oxycedrus* L. *J Ethnopharmacol* 2003; 85: 231-5.
- 2 Mukherjee PK, Saritha GS, Suresh B. Antimicrobial potential of two different *Hypericum* species available in India. *Phytother Res* 2002; 16: 692-5.
- 3 Sofowora A.E. Medicinal plants and traditional medicine in Africa. 2<sup>nd</sup> edition, Spectrum Books Ltd., Ibadan, Nigeria; 1993. p. 289.
- 4 Yang X, Summerhurst DK, Koval SF, et al. Isolation of an antimicrobial compound from *Impatiens balsamina* L. using bioassay-guided fractionation. *Phytother Res* 2001; 15: 676-80.
- 5 Meurer-Grimes B, McBeth DL, Hallihan B, et al. Antimicrobial activity in medicinal plants of the Scrophulariaceae and Acanthaceae. *Pharm Biol* 1996; 34: 243-8.
- 6 Berrondo LF, Teixeira GF, Sidnei BO, et al. Dirhamnosyl flavonol and other constituents from *Brillantaisia palisatii*. *Química Nova* 2003; 26: 10.
- 7 Csurhes S, Edwards R. Potential environmental weeds in Australia: Candidate species for preventative control. Canberra, Australia. Biodiversity Group, Environment Australia; 1998. p. 208.
- 8 Tamokou JD, Kuate JR, Tene M, Tane P. Antimicrobial clerodane diterpenoids from

- Microglossa angolensis* Oliv. et Hiern. *Indian J Pharmacol* 2009; 41: 60-3.
- 9 Tamokou JD, Tala FM, Wabo KH, et al. Antimicrobial activities of methanol extract and compounds from stem bark of *Vismia rubescens*. *J Ethnopharmacol* 2009; 124: 571-5.
  - 10 Tamokou JD, Kuate JR, Njateng GSS, et al. Antimicrobial activity of dichloromethane-methanol (1:1 v/v) extract from the stem bark of *Coula edulis* Bail. (Olacaceae). *Res J Microbiol* 2008; 3: 414-22.
  - 11 Tene M, Ndontsa BL, Tane P, et al. Antimicrobial diterpenoids and triterpenoids from the stem bark of *Croton macrostachys*. *Int J Biol Chem Sci* 2009; 3: 538-44.
  - 12 Kuate JR, Mouokeu S, Wabo KH, et al. Antidermatophytic triterpenoids from *Syzygium jambos* (L.) Alston (Myrtaceae). *Phytother Res* 2007; 21: 149-52.
  - 13 Gatsing D, Tchakounte V, Ngamga D, et al. *In vitro* antibacterial activity of *Crinum purpurascens* Herb. leaf extract against the *Salmonella* species causing typhoid fever and its toxicological evaluation. *Iran J Med Sci* 2009; 34: 126-36.
  - 14 Banerji A, Ray R. Aurantioides: A new class of modified dipeptides from *Piper aurantiacum*. *Phytochemistry* 1981; 20: 2217-20.
  - 15 Tene M, Tane P, Tamokou JD, et al. Degraded diterpenoids from the stem bark of *Neoboutonia mannii*. *Phytochemistry Lett* 2008; 1: 120-4.
  - 16 Nyaa TBL, Tapondjou AL, Barboni L, et al. NMR assignment and Antimicrobial/ antioxidant activities of 1 $\beta$ -hydroxyeuscaphic acid from the seeds of *Butyrospermum parkii*. *Nat Prod Sci* 2009; 15: 76-82.
  - 17 Kuete V, Nguemeving JR, Penlap Beng V, et al. Antimicrobial activity of the methanolic extracts and compounds from *Vismia laurentii* De Wild (Guttiferae). *J Ethnopharmacol* 2007; 109: 372-9.
  - 18 Djoukeng JD, Abou-Mansour E, Tabacchi R, et al. Antibacterial triterpenes from *Syzygium guineense* (Myrtaceae). *J Ethnopharmacol* 2005; 101: 283-6.
  - 19 Ragasa CY, Penalosa BA, Rideout JA. A bioactive dipeptide derivative from *Malachra fasciata*. *Philippine J Sci* 1998; 127: 267-76.
  - 20 Singh B, Singh S. Antimicrobial activity of terpenoids from *Trichodesma amplexicaule* Roth. *Phytother Res* 2003; 17: 814-6.
  - 21 Cowan MM. Plant products as antimicrobial agents. *Clin Microbiol Rev* 1999; 12: 564-82.
  - 22 Arvind Sh, Reg FC, Enzo AP. Identification of antimicrobial component of an ethanolic extract of Australian medicinal plant, *Eremophila duttonii*. *Phytother Res* 2004; 18: 615-8.
  - 23 Mims CA, Playfair JHL, Roitt IM, et al. *Antimicrobials and chemotherapy*. In: Mims CA, eds. *Med. (eds.)*. *Med Microbiol Rev* 1993; 35: 1-34.
  - 24 Bowersox J. "Experimental Staph Vaccine Broadly Protective in Animal Studies", NIH, 1999-05-27. Retrieved on 2007-07-28.
  - 25 CPC. Rapport d'activités du Centre Pasteur du Cameroun 2001-2002. 2002. p. 189.
  - 26 Mohammad AH, Shigefumi M, Kataro M, et al. *In vitro* and *in vivo* activities of SCH56592 against *Cryptococcus neoformans*. *J Antimicrob Chemother* 1999; 44: 827-9.
  - 27 Fidel P, Lynch M, Sobel J. Candida-specific TH1-type responsiveness in mice with experimental vaginal candidiasis. *Infect Immun* 1993; 61: 4202-7